Precise targeting and controlled drug release can significantly enhance the therapeutic efficacy of cancer treatment. Trackable smart drug delivery systems have gained attention in the past decade because they can

Over the past decade, oncology research has ushered in tremendous advances in the understanding of genes that can mutate and cause cancer. But what, exactly, is going awry with those

Over 18,000 leaders in Biotech and Pharma attended the 2018 BIO convention. This year the Avacta team will be exhibiting and will be found on booth 3559. Further information about

In a recent article over at genengnews.com Sue Pearson discusses ‘Antibody Mimetics – More effective treatments for solid tumors?’ and the use of Avacta Group plc (LON:AVCT) Affirmers. Alastair Smith, Chief

“The sad fact is that around 70% of cancer patients with solid based tumors don’t respond to classical chemotherapy,” said Joseph Tabernero, MD, PhD, head of Val d’Hebron Institute of

Attending WRIB next week? The Avacta team are, and will be found on booth 61. A Week of Bioanalysis, Biomarkers, and Immunogenecity at WRIB Avacta Group Plc (LON:AVCT) principal focus

Avacta has been listed in Business Weekly’s “The Killer 50: Ones2Watch” Avacta Group Plc (LON:AVCT) principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to